Well it wasn't in clinical trials at the time of t
Post# of 72440
(Total Views: 222)
Posted On: 02/12/2018 6:45:54 PM
Re: Loose Lips #41912
Well it wasn't in clinical trials at the time of the deal. It's $50M upfront, part of which has to go toward phase 1 costs. Then, if it makes it into phase 2B they get another $125M. If they opt to move forward after a successful phase 2B they will pay out another $200M. J&J isn't putting up $1B for a preclinical drug, they're putting up $50M with payment structures in place as it advances.
Also keep in mind this is an oral drug for Crohn's. That's quite a bit more fashionable than a retention enema for Ulcerative Proctitis. Very different animals as far a valuation goes. If we developed an oral delivery form that treats Crohn's or UC, then we would have earned the $50M and would be on the cusp of claiming $125M to start a phase 2B.
Go IPIX!
Also keep in mind this is an oral drug for Crohn's. That's quite a bit more fashionable than a retention enema for Ulcerative Proctitis. Very different animals as far a valuation goes. If we developed an oral delivery form that treats Crohn's or UC, then we would have earned the $50M and would be on the cusp of claiming $125M to start a phase 2B.
Go IPIX!
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.
Scroll down for more posts ▼